Equities research analysts expect Dova Pharmaceuticals Inc (NASDAQ:DOVA) to post ($0.72) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Dova Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.66) and the lowest estimate coming in at ($0.77). Dova Pharmaceuticals reported earnings of ($0.36) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 100%. The firm is scheduled to report its next quarterly earnings report on Thursday, February 21st.
According to Zacks, analysts expect that Dova Pharmaceuticals will report full year earnings of ($2.63) per share for the current financial year, with EPS estimates ranging from ($2.69) to ($2.57). For the next financial year, analysts anticipate that the firm will report earnings of ($2.06) per share, with EPS estimates ranging from ($2.78) to ($1.04). Zacks’ EPS averages are an average based on a survey of research analysts that cover Dova Pharmaceuticals.
Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings results on Thursday, November 8th. The company reported ($0.69) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.12. The company had revenue of $2.93 million for the quarter, compared to analysts’ expectations of $2.66 million.
A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its stake in Dova Pharmaceuticals by 0.8% in the third quarter. BlackRock Inc. now owns 1,154,232 shares of the company’s stock worth $24,204,000 after purchasing an additional 9,312 shares during the period. Nexthera Capital LP increased its stake in Dova Pharmaceuticals by 25.2% in the third quarter. Nexthera Capital LP now owns 1,026,906 shares of the company’s stock worth $21,534,000 after purchasing an additional 206,558 shares during the period. Vanguard Group Inc. increased its stake in Dova Pharmaceuticals by 2.5% in the third quarter. Vanguard Group Inc. now owns 619,604 shares of the company’s stock worth $12,993,000 after purchasing an additional 14,985 shares during the period. Wells Fargo & Company MN increased its stake in Dova Pharmaceuticals by 12.7% in the second quarter. Wells Fargo & Company MN now owns 380,455 shares of the company’s stock worth $11,383,000 after purchasing an additional 42,819 shares during the period. Finally, Candriam Luxembourg S.C.A. increased its stake in Dova Pharmaceuticals by 95.6% in the third quarter. Candriam Luxembourg S.C.A. now owns 233,200 shares of the company’s stock worth $4,890,000 after purchasing an additional 114,000 shares during the period. Institutional investors and hedge funds own 37.14% of the company’s stock.
NASDAQ:DOVA traded up $0.06 during midday trading on Friday, hitting $14.48. 151,289 shares of the company traded hands, compared to its average volume of 176,013. Dova Pharmaceuticals has a 12-month low of $14.09 and a 12-month high of $37.00. The firm has a market capitalization of $406.70 million, a PE ratio of -10.34 and a beta of 0.71. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.40 and a current ratio of 7.50.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Recommended Story: Understanding Analyst Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.